Innate Pharma to participate in upcoming investor conferences
Innate Pharma to return US and EU Lumoxiti commercialization rights to AstraZeneca
Innate Pharma to present additional efficacy data for monalizumab in combination with cetuximab in head and neck cancer at the ESMO immuno-oncology virtual congress
Innate Pharma 2021 financial calendar
Innate Pharma reports third quarter 2020 financial results and business update
Innate Pharma receives PRIME designation from the European Medicines Agency for lacutamab in Sézary syndrome
Innate Pharma to participate in upcoming investor conferences
Innate Pharma launches HopeConnectLearn: a new online resource for hairy cell leukemia patients
First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca
Number of shares and voting rights of Innate Pharma as of October 1, 2020
